Merrimack, Ipsen deal

Ipsen will acquire the commercial business of Merrimack, including U.S. rights to Onivyde irinotecan and Merrimack’s generic doxorubicin product. The companies expect the deal to close this quarter. Merrimack markets Onivyde to

Read the full 322 word article

User Sign In